[Non oncologic applications of molecular targeted therapies]. / Applications thérapeutiques non oncologiques des thérapies moléculaires ciblées.
Bull Cancer
; 99(10): 953-62, 2012 Oct.
Article
en Fr
| MEDLINE
| ID: mdl-23092598
ABSTRACT
Significant improvements in the knowledge of cancer biology have permitted the development of new molecular targeted therapies. Meanwhile, a better understanding of the physiology of various non-cancerous diseases has allowed developing these agents in other areas. This review intends to illustrate these perspectives through examples corresponding to different strategies of molecular-targeted therapies use of a monoclonal antibody binding a receptor (rituximab and rheumatoid arthritis) or a ligand (bevacizumab and age-related macular degeneration), tyrosine kinase inhibitor (imatinib and systemic sclerosis) or inhibitor of cytoplasmic signal transduction pathways (immunosuppressive and antiproliferative effects of mammalian target of rapamycin [mTOR] inhibitors). Clinical results can draw today what could become molecular medicine of tomorrow.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Artritis Reumatoide
/
Esclerodermia Sistémica
/
Terapia Molecular Dirigida
/
Degeneración Macular
Límite:
Humans
Idioma:
Fr
Revista:
Bull Cancer
Año:
2012
Tipo del documento:
Article
País de afiliación:
Francia